Summary
Abbott Laboratories (ABT) filed an 8-K on April 18, 2017, primarily to update investors on the financial reporting structure following the January 4, 2017, acquisition of St. Jude Medical. The company is enhancing transparency by breaking down its Cardiovascular and Neuromodulation (ACN) business into six detailed product categories: Rhythm Management, Electrophysiology, Heart Failure, Vascular, Structural Heart, and Neuromodulation. This change will provide investors with a more granular view of performance within these critical segments. The filing also references Exhibit 99.1, which contains comparable revenue data for these new categories for each quarter of 2016 and the full year. This historical data is crucial for investors to establish a baseline and understand the ongoing performance trends of the integrated ACN business, especially as Abbott moves forward with the combined operations. Investors should review this exhibit to gauge the historical revenue contributions of each segment prior to the St. Jude acquisition's full impact.
Key Highlights
- 1Abbott Laboratories is enhancing financial reporting for its Cardiovascular and Neuromodulation (ACN) business post-St. Jude Medical acquisition.
- 2The ACN business will now be reported across six distinct product categories: Rhythm Management, Electrophysiology, Heart Failure, Vascular, Structural Heart, and Neuromodulation.
- 3This new reporting structure aims to provide investors with greater detail and insight into the performance of specific product lines within the ACN segment.
- 4Comparable revenue data for these new categories for the full year 2016 and each quarter of 2016 is provided in Exhibit 99.1.
- 5The acquisition of St. Jude Medical was completed on January 4, 2017.
- 6The new reporting categories will be effective starting with the first quarter of 2017.
- 7The information provided is furnished and not deemed 'filed' for certain SEC purposes.